Navigation Links
Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
Date:6/11/2008

nt candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligat
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
2. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
3. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
4. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
5. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
6. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
7. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
8. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
9. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Announces $40 Million Private Placement
11. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... The Alliance for Clinical ... non-profit collaborative building a global system to enhance ... announced Phase 3 of its Site Accreditation and ... H. Kalali, Vice-President, Global Head, Neuroscience Center of ... and Quality Integration (CQI) Consulting will lead the ...
(Date:9/16/2014)... strap that can harvest energy from jaw movements has ... , It is hoped that the device can generate ... number of small-scale implantable or wearable electronic devices, such ... communication devices. , The first results of the device,s ... Publishing,s journal Smart Materials and Structures . , ...
Breaking Biology Technology:Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2
... ... in Arizona ,with State of the Art 3D Dedicated Neurology Suite, , ... (PRWEB) June 28, 2010 -- ... in the state of Arizona to adopt TrueVision® 3D Surgical Visualization, where multiple 3D ...
... ORLANDO, Fla. , June 26 Orexigen® Therapeutics, ... open-label study demonstrating that treatment with Contrave® resulted in significant improvements ... control of eating in overweight and obese patients with major depression. ... The ...
... 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... an integrated database of clinical studies that showed no ... (pramlintide acetate) injection use compared to a pooled comparator ... findings were presented at the 70th Annual Scientific Sessions ...
Cached Biology Technology:Cardon Children's Medical Center Adopts TrueVision 3D Surgical Visualization Platform for Department of Pediatric Neurosurgery 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 3Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 4Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 2Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 3Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 6Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 7
(Date:9/16/2014)... consumers to make ethical choices such as buying clothing ... on fair-trade coffee, and bringing their own bags when ... the Journal of Consumer Research , ethical consumption ... their emotions about unethical practices into action. , "Advocates ... environmental and human costs of the products they choose, ...
(Date:9/16/2014)...  Valencell, Inc., a leader in performance biometric data ... "Showcase Companies" representing North Carolina,s ... Venture Conference on September 16-17 th at the ... Raleigh, North Carolina . Valencell,s President Dr. ... the "Digital Health Spotlight Sector" on how the Company,s ...
(Date:9/16/2014)... of wild foods, autumn harks a season of bounty. ... luring intrepid collectors to woodlands in search of elusive ... in the allure of the treasure hunt, and their ... existence. But are the mushrooms which you are eating ... diverse yet vastly underdocumented although some estimates range ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3
... Over 50 leading experts will meet today in Brussels, ... cocoa flavanol research and the key findings of FLAVIOLA ... flavanols, their health benefits and potential applications. Members of ... of international researchers to review the outcomes of FLAVIOLA,s ...
... What cancerous conditions lead to what kinds of bacterial infections? ... benefit from pre-treatment with certain kinds of antibiotics. A University ... of the International Journal of Infectious Diseases shows ... are especially prevalent in patients with lung and GI ...
... that are socially isolated during a critical period of ... alcohol, found researchers at The University of Texas at ... the socially isolated rats. These effects, which are ... persist even after the rats are reintroduced into the ...
Cached Biology News:Recent breakthroughs in cocoa flavanol research discussed by European research consortium and expert panel 2Planning for bacteria in cancer patients may help hospitals fight infections 2Socially isolated rats are more vulnerable to addiction, report researchers 2Socially isolated rats are more vulnerable to addiction, report researchers 3
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
Request Info...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Biology Products: